8-K: Paysign Reports Record Q3 Revenue, Upwardly Revises 2025 Outlook

Paysign, Inc. announced strong third quarter 2025 financial results with record revenue and improved profitability, leading to an upward revision of its full-year 2025 guidance.

Summary

• Total revenues for Q3 2025 reached $21.60 million, marking a 41.6% increase from Q3 2024.
• Net income for the quarter was $2.22 million, up 54.2% year-over-year, with diluted earnings per share at $0.04.
• Adjusted EBITDA grew 78.1% to $5.04 million (23.3% of revenues) in Q3 2025, compared to $2.83 million (18.5% of revenues) in Q3 2024.
• Pharma patient affordability revenue surged 141.9% to $7.92 million, with 105 active programs and over 60% increase in processed claims.
• Plasma revenue increased 12.4% to $12.86 million, with 595 plasma centers at quarter-end, an increase of 117 centers over the past 12 months.
• Gross profit increased 43.4% to $12.15 million, with gross margin improving from 55.5% to 56.3%.
• Exited the quarter with $7.53 million in unrestricted cash and zero bank debt, though unrestricted cash was reduced by $9.36 million due to payment timing on passthrough claim reimbursement receivables.
• Full-year 2025 total revenue is now estimated between $80.5 million and $81.5 million, reflecting 38.7% year-over-year growth at the midpoint.
• Full-year 2025 net income is projected to be between $7.0 million and $8.0 million, or $0.12 to $0.13 per diluted share.
• Full-year 2025 Adjusted EBITDA is expected to range from $19.0 million to $20.0 million, or $0.32 to $0.34 per diluted share.

Sentiment

Score: 9

Explanation: The filing presents exceptionally strong financial results for Q3 2025, with record revenue, significant profit growth, and improved margins. The upward revision of full-year guidance, particularly driven by the high-growth pharma segment, indicates strong positive momentum and confidence in future performance. While there are minor headwinds in the plasma segment, the overall picture is very positive.

Positives

• Record total revenues of $21.60 million in Q3 2025, up 41.6% year-over-year.
• Significant improvement in net income, up 54.2% to $2.22 million.
• Adjusted EBITDA increased 78.1% to $5.04 million, with Adjusted EBITDA margin improving by 480 basis points to 23.3%.
• Exceptional growth in pharma patient affordability revenue, up 141.9%, driven by 39 net new programs over 12 months and increased average revenue per program.
• Plasma revenue returned to year-over-year growth, increasing 12.4%, with 117 net plasma centers added over the past 12 months.
• Gross profit margin improved by 70 basis points to 56.3%, primarily due to a greater contribution from the higher-margin pharma patient affordability business.
• Operating margin improved by 280 basis points to 7.3%, and net margin improved by 90 basis points to 10.3%.
• Zero bank debt and a strong cash position, despite temporary reductions due to payment timing.
• Upward revision of full-year 2025 estimated results for total revenues, net income, and Adjusted EBITDA.
• Opened a new 30,000-square-foot customer service contact center, increasing support capacity fourfold to meet surging demand.

Negatives

• Average monthly revenue per plasma center decreased to $7,122 compared to $7,991 for the same period last year, attributed to a decline in plasma donations and dollars loaded to cards as plasma inventory levels normalized.
• Exited the quarter with 595 plasma centers, a reduction of 12 centers from the prior quarter due to planned closures of underperforming centers from one customer.
• Unrestricted cash was reduced at quarter-end by $9.36 million related to payment timing on passthrough claim reimbursement receivables and related payables.

Risks

• Inability to continue the current growth rate in future periods.
• A downturn in the economy could reduce the customer base and demand for products and services, adversely affecting business, financial condition, profitability, and cash flows.
• Operating in a highly regulated environment, with potential for failure by the company or business partners to comply with applicable laws and regulations.
• Changes in laws, regulations, credit card association rules, or other industry standards affecting the business.
• A data security breach could expose the company to liability and protracted and costly litigation.
• Other risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

Paysign has revised its full-year 2025 estimated results upward, anticipating total revenues between $80.5 million and $81.5 million, net income between $7.0 million and $8.0 million, and Adjusted EBITDA between $19.0 million and $20.0 million. The company expects fourth-quarter results to be similar to the third quarter, with flat plasma revenue, continued launch of additional patient affordability programs, and seasonally lower claim activity. The industry-wide oversupply of plasma inventories is expected to abate in the first half of 2026, which should benefit the plasma business.

Management Comments

• "Q3 2025 proved once again to be a record-breaking quarter for Paysign. Our revenue soared to $21.6 million, reflecting an outstanding 41.6% year-over-year growth rate. Adjusted EBITDA reached a new high of $5.0 million, up 78.1%, while net income improved by a healthy 54.2% to $2.2 million. These results underscore the exceptional momentum and improving operational efficiencies driving our business forward." Mark Newcomer, President and CEO.
• "Our pharma patient affordability business continues to exceed expectations, growing an impressive 141.9%. We ended the quarter with 105 active programs and anticipate adding another 20-30 programs before year end, a testament to the strong demand for our innovative solutions." Mark Newcomer, President and CEO.
• "With this enhanced infrastructure [new customer service contact center], we are fully prepared to capitalize on the tremendous growth opportunities ahead and continue setting new standards for excellence." Mark Newcomer, President and CEO.
• "With patient affordability continuing its exceptional growth trajectory, growth returning to plasma, and the many opportunities that lie ahead for our SaaS engagement technology solutions, we are well-positioned to deliver long term value to our shareholders." Mark Newcomer, President and CEO.
• "Our gross profit margins improved by 70 basis points (bps) from 55.5% to 56.3%, due to a greater percentage of pharma patient affordability revenues, offset by the new plasma centers not being fully mature as well as additional costs associated with our new customer service contact center. Our operating margin improved by 280 bps from 4.5% to 7.3%, our net margin improved by 90 bps, from 9.4% to 10.3% and our Adjusted EBITDA margin improved by 480 bps, from 18.5% to 23.3%, demonstrating the operating leverage inherent in our business model while still making significant investments in people and infrastructure to ensure the success of our growing businesses." Jeff Baker, Paysign CFO.

Industry Context

Paysign's strong performance is largely driven by the robust demand in the pharma patient affordability sector, which is experiencing significant growth. This growth helps offset challenges in the plasma donor compensation business, where an industry-wide oversupply of plasma inventories has led to a decline in average revenue per center, though this oversupply is expected to abate in the first half of 2026. The company's investment in SaaS donor engagement technologies positions it to capitalize on future opportunities in the blood and plasma collection space, pending FDA approval.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, upward revised outlook, and share repurchase activity, indicating enhanced shareholder value.
• Employees: Positive impact from continued hiring to support growth, investment in a new customer service contact center, and stock-based compensation for retention, suggesting job security and growth opportunities.
• Customers (Pharma): Positive impact from increased active programs and enhanced support capacity through the new contact center, leading to better service and innovative solutions.
• Customers (Plasma): Mixed impact; while new centers were added and SaaS technologies are well-received, average revenue per center declined due to industry oversupply, which is expected to abate in H1 2026.
• Creditors: Positive impact due to zero bank debt and improved financial health, indicating lower credit risk.

Next Steps

• Anticipate adding another 20-30 pharma patient affordability programs before year-end 2025.
• Continue showcasing SaaS donor engagement technologies to the plasma industry.
• Await FDA 510(k) approval on the donor management system targeted at the blood and plasma collection space.
• Prepare for significant acceleration in the patient affordability business in the new year (2026).
• Monitor the abatement of industry-wide oversupply of plasma inventories, expected in the first half of 2026.

Key Dates

Recommendation

Paysign's Q3 2025 results demonstrate exceptional growth, particularly in the high-margin pharma patient affordability segment, which is driving significant revenue and profit expansion. The company's operational efficiencies are clearly improving, as evidenced by substantial increases in net income, Adjusted EBITDA, and all key margin metrics. The upward revision of full-year 2025 guidance signals strong management confidence and continued momentum. Despite some temporary headwinds in the plasma business due to industry oversupply, the company is strategically positioned with new technologies and infrastructure investments to capitalize on future growth. With zero bank debt and a focus on high-growth areas, Paysign presents a compelling investment opportunity for long-term value creation.

Keywords

Paysign, PAYS, financial results, Q3 2025, earnings, revenue, net income, Adjusted EBITDA, pharma patient affordability, plasma donor compensation, prepaid cards, fintech, healthcare technology, payment processing, corporate governance, risk management, financial reporting